Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Active not recruiting 5Not yet recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1CNS 1

Conditions

Melanoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 9fludarabine phosphate 5fludarabine 5atezolizumab 4Paclitaxel 4Nivolumab 4Cyclophosphamide 4Cisplatin 4Cetuximab 4Carboplatin 4durvalumab 3Specimen Handling 3Pemetrexed 3Docetaxel 3Bevacizumab 3venetoclax 2ibrutinib 2encorafenib 2binimetinib 2Trastuzumab 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Practice Guidelines as Topic 2Platinum 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ipilimumab 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × lenvatinib × 30 days × Clear all
NCT04955743 2026-06-04

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Yale University

Phase 2 Terminated
18 enrolled 13 charts
CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡